Q2 FY2026 EarningsQ2 FY2026 performance was mixed, with revenue of $218.4M missing the $221.8M consensus by 1.5%. Despite the top-line miss, AUVELITY® sales grew 51% YoY to $180.3M, and GAAP EPS of -$0.99 missed the -$0.89 consensus primarily due to heavy SG&A spending ($208.1M) linked to new product launches. Management provided an optimistic outlook for cash runway, expecting current reserves to fund operations until cash flow positivity.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Axsome Therap(AXSM) the Revenue is 218.38 M (+45.54%), Miss estimate;the EBIT is -49.65 M (-35.22%), Miss estimate;the EPS is -0.99 (-2.06%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.22B45.54%
0.22B47.81%
-0.00B2.27%
EBITMiss expectations
-0.05B35.22%
-0.04B4.14%
-0.01B31.08%
EPSMiss expectations
-0.992.06%
-0.858111.53%
-0.131913.59%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf